Filing Flows › Aligos Therapeutics (ALGS) › Who owns the stock
Who owns Aligos Therapeutics (ALGS) stock
32 funds reported Aligos Therapeutics (ALGS) shares in their latest 13F filings, worth $15.1M in all. The largest holder is Deep Track Capital, LP ($2.6M). Last quarter 12 funds added to their stakes and 15 cut them.
Largest holders (13F)
| Fund | Shares | Value | Change | Quarter |
|---|---|---|---|---|
| Deep Track Capital, LP | 444,110 | $2.6M | unchanged | 2026-06-30 |
| Alyeska Investment Group, L.P. | 412,000 | $2.4M | unchanged | 2026-06-30 |
| Sio Capital Management, LLC | 327,237 | $1.9M | unchanged | 2026-06-30 |
| Vanguard Group | 200,395 | $1.9M | increase | 2025-12-31 |
| Marshall Wace, LLP | 246,579 | $1.4M | decrease | 2026-06-30 |
| Woodline Partners LP | 177,362 | $1.0M | unchanged | 2026-06-30 |
| Vanguard Capital Management LLC | 175,543 | $1.0M | decrease | 2026-06-30 |
| Baker Bros. Advisors LP | 83,055 | $479K | unchanged | 2026-06-30 |
| Hhlr Advisors | 76,247 | $440K | unchanged | 2026-06-30 |
| D. E. Shaw | 66,463 | $383K | increase | 2026-06-30 |
| UBS Group AG | 59,986 | $346K | increase | 2026-06-30 |
| Geode Capital Management, LLC | 47,173 | $272K | decrease | 2026-06-30 |
| Jane Street Group, LLC | 32,402 | $187K | new | 2026-06-30 |
| BlackRock | 30,292 | $175K | increase | 2026-06-30 |
| Vanguard Fiduciary Trust | 28,612 | $165K | increase | 2026-06-30 |
Aligos Therapeutics' latest quarter
Aligos Therapeutics, Q3 2026: revenue $2.8M (+282% year over year), operating margin -773.5%, net loss $21.9M, operating cash flow $1.5M. The chart follows the revenue to costs, profit and cash.
Questions
Who owns the most ALGS stock?
By the latest 13F filings: Deep Track Capital, LP ($2.6M); Alyeska Investment Group, L.P. ($2.4M); Sio Capital Management, LLC ($1.9M); Vanguard Group ($1.9M); Marshall Wace, LLP ($1.4M).
What is the short interest in ALGS?
707,471 shares were sold short at the 2026-10-15 settlement, -0.18% of the float.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.